Literature DB >> 18480098

Schizophrenia: a concise overview of incidence, prevalence, and mortality.

John McGrath1, Sukanta Saha, David Chant, Joy Welham.   

Abstract

Recent systematic reviews have encouraged the psychiatric research community to reevaluate the contours of schizophrenia epidemiology. This paper provides a concise overview of three related systematic reviews on the incidence, prevalence, and mortality associated with schizophrenia. The reviews shared key methodological features regarding search strategies, analysis of the distribution of the frequency estimates, and exploration of the influence of key variables (sex, migrant status, urbanicity, secular trend, economic status, and latitude). Contrary to previous interpretations, the incidence of schizophrenia shows prominent variation between sites. The median incidence of schizophrenia was 15.2/100,000 persons, and the central 80% of estimates varied over a fivefold range (7.7-43.0/100,000). The rate ratio for males:females was 1.4:1. Prevalence estimates also show prominent variation. The median lifetime morbid risk for schizophrenia was 7.2/1,000 persons. On the basis of the standardized mortality ratio, people with schizophrenia have a two- to threefold increased risk of dying (median standardized mortality ratio = 2.6 for all-cause mortality), and this differential gap in mortality has increased over recent decades. Compared with native-born individuals, migrants have an increased incidence and prevalence of schizophrenia. Exposures related to urbanicity, economic status, and latitude are also associated with various frequency measures. In conclusion, the epidemiology of schizophrenia is characterized by prominent variability and gradients that can help guide future research.

Entities:  

Mesh:

Year:  2008        PMID: 18480098     DOI: 10.1093/epirev/mxn001

Source DB:  PubMed          Journal:  Epidemiol Rev        ISSN: 0193-936X            Impact factor:   6.222


  545 in total

Review 1.  Genome-wide approaches to schizophrenia.

Authors:  Jubao Duan; Alan R Sanders; Pablo V Gejman
Journal:  Brain Res Bull       Date:  2010-04-28       Impact factor: 4.077

Review 2.  Pharmacogenetics and antipsychotics: therapeutic efficacy and side effects prediction.

Authors:  Jian-Ping Zhang; Anil K Malhotra
Journal:  Expert Opin Drug Metab Toxicol       Date:  2011-01       Impact factor: 4.481

3.  Schizophrenia and vitamin D related genes could have been subject to latitude-driven adaptation.

Authors:  Roberto Amato; Michele Pinelli; Antonella Monticelli; Gennaro Miele; Sergio Cocozza
Journal:  BMC Evol Biol       Date:  2010-11-11       Impact factor: 3.260

Review 4.  Cognitive behavioural therapy (brief versus standard duration) for schizophrenia.

Authors:  Farooq Naeem; Saeed Farooq; David Kingdon
Journal:  Cochrane Database Syst Rev       Date:  2015-10-21

5.  Conceptualization and treatment of negative symptoms in schizophrenia.

Authors:  Sonali Sarkar; Kiley Hillner; Dawn I Velligan
Journal:  World J Psychiatry       Date:  2015-12-22

6.  Subclinical psychosis syndromes in the general population: results from a large-scale epidemiological survey among residents of the canton of Zurich, Switzerland.

Authors:  W Rössler; V Ajdacic-Gross; H Haker; S Rodgers; M Müller; M P Hengartner
Journal:  Epidemiol Psychiatr Sci       Date:  2013-11-26       Impact factor: 6.892

7.  Cardiovascular disease risk in schizophrenia patients: a case control study.

Authors:  Kedar B Joshi; Anup Nillawar; A P Thorat
Journal:  J Clin Diagn Res       Date:  2013-11-25

8.  The Neurobiological Basis for Social Affiliation in Autism Spectrum Disorder and Schizophrenia.

Authors:  Amanda Crider; Anilkumar Pillai
Journal:  Curr Behav Neurosci Rep       Date:  2016-04-16

9.  A meta-analysis of cardio-metabolic abnormalities in drug naïve, first-episode and multi-episode patients with schizophrenia versus general population controls.

Authors:  Davy Vancampfort; Martien Wampers; Alex J Mitchell; Christoph U Correll; Amber De Herdt; Michel Probst; Marc De Hert
Journal:  World Psychiatry       Date:  2013-10       Impact factor: 49.548

10.  Gene expression elucidates functional impact of polygenic risk for schizophrenia.

Authors:  Menachem Fromer; Panos Roussos; Solveig K Sieberts; Jessica S Johnson; David H Kavanagh; Thanneer M Perumal; Douglas M Ruderfer; Edwin C Oh; Aaron Topol; Hardik R Shah; Lambertus L Klei; Robin Kramer; Dalila Pinto; Zeynep H Gümüş; A Ercument Cicek; Kristen K Dang; Andrew Browne; Cong Lu; Lu Xie; Ben Readhead; Eli A Stahl; Jianqiu Xiao; Mahsa Parvizi; Tymor Hamamsy; John F Fullard; Ying-Chih Wang; Milind C Mahajan; Jonathan M J Derry; Joel T Dudley; Scott E Hemby; Benjamin A Logsdon; Konrad Talbot; Towfique Raj; David A Bennett; Philip L De Jager; Jun Zhu; Bin Zhang; Patrick F Sullivan; Andrew Chess; Shaun M Purcell; Leslie A Shinobu; Lara M Mangravite; Hiroyoshi Toyoshiba; Raquel E Gur; Chang-Gyu Hahn; David A Lewis; Vahram Haroutunian; Mette A Peters; Barbara K Lipska; Joseph D Buxbaum; Eric E Schadt; Keisuke Hirai; Kathryn Roeder; Kristen J Brennand; Nicholas Katsanis; Enrico Domenici; Bernie Devlin; Pamela Sklar
Journal:  Nat Neurosci       Date:  2016-09-26       Impact factor: 24.884

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.